Screener
Tarsus Pharmaceuticals, Inc. TARS Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other income (expense), net | (281) | (145) | (368) | (226) |
| Total other income (expense), net | 4,073 | 1,844 | 5,580 | 3,004 |
| Provision for income taxes | (2,716) | — | (5,068) | — |
| Net loss | $(18,551) | $(20,340) | $(25,518) | $(45,460) |
| Unrealized gain (loss) on marketable securities and cash equivalents | (259) | (46) | (938) | (140) |
| Comprehensive loss | $(18,810) | $(20,386) | $(26,456) | $(45,600) |
| Net loss per share, basic and diluted | $(0.43) | $(0.48) | $(0.59) | $(1.11) |
| Weighted-average shares outstanding, basic and diluted | 43,393,643 | 42,360,452 | 43,176,514 | 40,869,364 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s business segments — net loss?
- Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — net loss of -$18.55M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s business segments — net loss changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s business segments — net loss increased by 8.8% year-over-year, from -$20.34M to -$18.55M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — net loss?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — net loss has grown at a 2.3% compound annual growth rate (CAGR), from -$62.09M to -$66.42M.
- What does business segments — net loss mean?
- Represents the bottom-line financial result of the business segment after accounting for all revenues, operating expenses, and non-operating items. A persistent net loss is common in growth-stage biopharmaceutical companies investing heavily in commercialization and R&D.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude